Inhibrx Stock Today
| INBX Stock | USD 14.10 0.05 0.36% |
PerformanceVery Weak
| Odds Of DistressLow
|
Inhibrx is trading at 14.10 as of the 2nd of April 2025; that is 0.36 percent increase since the beginning of the trading day. The stock's open price was 14.05. Inhibrx has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Inhibrx symbol was changed from INXB,INXBV on 31st of May 2024. The performance scores are derived for the period starting the 3rd of March 2025 and ending today, the 2nd of April 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of August 2020 | Category Healthcare | Classification Health Care |
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.48 M outstanding shares of which 955.4 K shares are currently shorted by private and institutional investors with about 13.81 trading days to cover. More on Inhibrx
Moving against Inhibrx Stock
Inhibrx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Older Symbol | INXB | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Management, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInhibrx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inhibrx's financial leverage. It provides some insight into what part of Inhibrx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibrx (INBX) is traded on NASDAQ Exchange in USA. It is located in 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037 and employs 156 people. Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB. Inhibrx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 203.39 M. Inhibrx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.48 M outstanding shares of which 955.4 K shares are currently shorted by private and institutional investors with about 13.81 trading days to cover.
Inhibrx currently holds about 176.38 M in cash with (194.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52.
Check Inhibrx Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Inhibrx is $203.39 Million. The majority of Inhibrx outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Inhibrx to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Inhibrx. Please pay attention to any change in the institutional holdings of Inhibrx as this could imply that something significant has changed or is about to change at the company. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Check Inhibrx Ownership Details
Inhibrx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dekabank Deutsche Girozentrale | 2024-09-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 0.0 |
Inhibrx Historical Income Statement
Inhibrx Stock Against Markets
Inhibrx Corporate Management
| Leah JD | Corporate VP | Profile | |
| Mark Lappe | Chairman, Founder | Profile | |
| Charbel PharmD | Vice Planning | Profile | |
| BS CPA | Chief Officer | Profile | |
| Jeffrey Jensen | Executive Officer | Profile | |
| Brendan Eckelman | Executive Officer | Profile | |
| Carlos Bais | Executive Sciences | Profile |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.